Stopping Ulcerative Colitis Progression in Its Tract:

Quality Payment Program + Earn ABIM MOC Credit



Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes

#stopUC

Provided By



June 3, 2018 • Breakfast at 6:00 am

Washington, DC • The Marriott Marquis, Liberty Ballroom

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

This program is not affiliated with Digestive Disease Week®.

Stopping Ulcerative Colitis Progression in Its Tract:

Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes



AGENDA

6:00 am Breakfast start time **6:30 am** Activity start time

FACULTY



David T. Rubin, MD, FACG, AGAF, FACP, FASGE (Moderator)

Joseph B. Kirsner Professor of Medicine Section Chief, Gastroenterology, Hepatology and Nutrition Co-Director, Digestive Diseases Center University of Chicago Medicine Chicago, IL



Miguel Regueiro, MD, AGAF, FACG, FACP

Chair, Department of Gastroenterology and Hepatology Vice Chair, Digestive Disease and Surgery Institute Professor of Medicine, Lerner College of Medicine Cleveland Clinic Cleveland, OH

TARGET AUDIENCE

Gastroenterologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with UC

COMMERCIAL SUPPORT STATEMENT

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

SYMPOSIUM DETAILS

For more information on this symposium and to pre-register visit **www.cmeoutfitters.com/StopUC** or scan the QR code on the right.



Stopping Ulcerative Colitis Progression in Its Tract:

Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes



LEARNING OBJECTIVES

- Examine the rationale for the use of early, effective treatment in altering the progressive course of ulcerative colitis (UC).
- Utilize the AGA UC Care Pathway to guide personalized biologic therapy to halt disease progression in UC.
- Incorporate disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC.

The following learning objectives pertain only to those requesting CNE or CPE credit:

- Examine the rationale for the use of early, effective treatment in altering the progressive course of ulcerative colitis (UC).
- Explain the AGA UC Care Pathway to guide personalized biologic therapy to halt disease progression in UC.
- Describe disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC.

ACCREDITATION

CME Credit (Physicians): CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses): Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours.

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

CPE Credit (Pharmacists): CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy
Education as a provider of continuing pharmacy education. 1.25 contact hours (0.125 CEUs)
Universal Activity Number: 0376-0000-18-014-L01-P
Type: knowledge-based

ABIM/MOC Credit: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

QUALITY PAYMENT PROGRAM

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Stopping Ulcerative Colitis Progression in Its Tract:

Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes





David T. Rubin, MD, FACG, AGAF, FACP, FASGE (Moderator)

Joseph B. Kirsner Professor of Medicine Section Chief, Gastroenterology, Hepatology and Nutrition Co-Director, Digestive Diseases Center University of Chicago Medicine Chicago, IL

BIOGRAPHY

Dr. Rubin earned a medical degree with honors at the University of Chicago Pritzker School of Medicine. He completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago, where he served as Chief Resident and Chief Fellow. Prior to his current appointments, Dr. Rubin served for 11 years as Director of the Gastroenterology, Hepatology and Nutrition fellowship program. He also currently serves as an associate faculty member at the MacLean Center for Clinical Medical Ethics and an associate investigator at the University of Chicago Comprehensive Cancer Center.

Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE) and the American College of Physicians (ACP) and an active national member of the Crohn's & Colitis Foundation of America (CCFA), and is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America's Top Physicians (gastroenterology). Additionally, he twice received the ACG's Governor's Award of Excellence in Clinical Research (2003 and 2013), the Cancer Research Foundation Young Investigator's Award (2004), and the UC Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the CCFA's Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He is currently the Chair of Government and Industry Affairs for the national CCFA, and in this role has authored or co-authored position and policy statements for the Foundation on behalf of patients and professionals. He is an Associate Editor of the journal Gastroenterology and Co-Editor of the ACG On-Line Educational Universe.

Dr. Rubin is the editor of a best-selling book on inflammatory bowel disease (IBD), now in its 2nd edition, and an author or coauthor of many peer-reviewed articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the in progress ACG Guidelines for ulcerative colitis. His current research is in the area of progressive complications from uncontrolled inflammation, the doctor-patient relationship in IBD, and a variety of collaborative studies related to the microbiome and intestinal disease.

He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular twitter feed @IBDMD. His principal research interests include novel IBD therapies and outcomes, colon cancer prevention, and clinical medical ethics.

Stopping Ulcerative Colitis Progression in Its Tract:

Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes





Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine, Lerner College of Medicine
Cleveland Clinic
Cleveland, OH

BIOGRAPHY

Dr. Regueiro earned his bachelor's degree at the University of Pennsylvania, his medical degree at Drexel (Hahnemann) University and completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School's Beth Israel Hospital.

Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure, and honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.

Dr. Regueiro is currently the Chair of the Department of Gastroenterology and Hepatology and Vice Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co-Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine, Cleveland Clinic.

Dr. Regueiro's main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn's disease. Recently, he has been involved in transformative medicine initiatives and developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs.

Stopping Ulcerative Colitis Progression in Its Tract:

Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes



DISCLOSURE DECLARATION

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Regueiro reports that he conducts research support for Abbvie Inc.; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from Abbvie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; UCB, Inc.

Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./ Roche; Janssen Pharmaceuticals, Inc.' Prometheus Laboratories Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; UCB, Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Amgen Inc.; Celgene Corporation; Forward Pharma; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Samsung Bioepis; Sandoz; Shire; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc. He is on the Board of Trustees for the American College of Gastroenterology; is Co-Founder and CFO of Cornerstones Health, Inc. (non-profit); and is Co-Founder of GoDuRn, LLC.

Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Stopping Ulcerative Colitis **Progression in Its Tract:**

Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes



OBTAINING CREDIT

In order to receive credit, please complete the evaluation/credit request form found on your table and turn them in to the CME Outfitters staff on your way out. Don't forget: If claiming ABIM MOC credit, please write ABIM # on your form.

DOWNLOADABLE RESOURCES

Downloadable resources will be available at www.cmeoutfitters.com/stopUCresources



CLAIM YOUR ABIM MOC CREDIT

In 3 Simple Steps

- 1. Actively participate in the meeting by responding to ARS and/or asking the faculty questions (It's ok if you miss answering a question or get them wrong, you can still claim MOC)
- 2. Complete the evaluation form found on your tables (For live stream participants, follow the credit claim link)
- 3. Be sure to fill in your ABIM ID number and DOB (MM/DD) on the evaluation, so we can submit your credit to ABIM.



Stopping Ulcerative Colitis Progression in Its Tract:

Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes



QUALITY PAYMENT PROGRAM IMPROVEMENT ACTIVITY

4 Steps for Completion

- 1. Actively participate in the meeting by responding to ARS and/or asking the faculty questions (It's ok if you miss answering a question or get them wrong)
- 2. Complete both
- The evaluation form found on your table
- The Quality Payment Improvement Activity form found on your table
- 3. Over the next 90 days, actively work to incorporate improvements in your clinical practice from this presentation
- 4. Complete the follow-up survey from CME Outfitters in approximately 3 months

We will then send you confirmation of your participation. To submit to CMS, clinicians must attest to their completion in a Quality Payment Program Improvement Activity.

GASTROENTEROLOGY DIGITAL HUB

Find free CE activities & resources necessary to optimize your approach to clinical care, as well as prior authorization (PA) activities & resources that will help the entire care team immediately improve the PA process to ensure consistent approvals that minimize administrative time & streamlines communications with payers.



www.cmeoutfitters.com/gastrohub

Stopping Ulcerative Colitis **Progression in Its Tract:**

Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes

INSTRUCTIONS FOR INTERACTIVE TECHNOLOGY

If you would like to use your tablet or mobile device to answer polling questions, view the onsite presentations, and submit questions to the faculty, please follow the instructions below:

1. Get Connected

- Please connect to the **CME Outfitters network** with your mobile device or laptop. This network does not have a password.
 - * Please note that this network is a local network and does NOT mean you're connected to the internet.
- Once you have joined the network, go to **arraylearn.com**.
- You are now connected to the symposium. All content and polling questions can be viewed on your device as long as you are connected to the above listed network.

2. Ask a Question to the Faculty

- Please click on "Ask a Question" and type your question. Please include the faculty member's name if the question is specifically for them. Your question will be sent to the faculty for the question and answer portion of the session.
- 3. View and Take Notes on Presentation Slides
- Please click on the "Take a Slide Note" button. If you did not enter
 your email address when you joined the meeting, you will be required
 to do so for note taking. When the meeting is complete, all your
 notes will be emailed to you within 5 business days.

ENGAGE WITH US ON TWITTER!

Follow us on **@cmeoutfitters** for announcements about upcoming CME opportunities, health care news, and more! We will be live tweeting from today's symposium – tweet us your questions using **#stopUC**

THANK YOU FOR JOINING US TODAY

This symposium will be available as a **web replay beginning July 19, 2018,** please check **www.CMEOutfitters.com** for more information on that date.